New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.
Start Your Search

Japanese Pill Kills Flu in 24 Hours

Japan has approved a single-dose drug called Xofluza that cured the flu in an average of 24 hours in a clinical trial.

Isao Teshirogi, CEO of Shionogi & Co. / Image: Kiyoshi Ota/Bloomberg
Isao Teshirogi, CEO of Shionogi & Co. / Image: Kiyoshi Ota/Bloomberg

This has been one of the worst years in history for influenza in the United States, but a recent Wall Street Journal article says there’s hope in a new pill that claims to cure the flu in just one day. The drug is called Xofluza, and it was developed by Japanese pharma company Shionogi. However, the drug won’t be available in the U.S. until 2019 at the earliest.

The only drug currently available in the U.S. to combat the flu is Tamiflu, but it doesn’t kill the virus. Rather, it lowers the odds a patient will experience severe complications like pneumonia. Xofluza works differently by inhibiting an enzyme the flu virus depends on to replicate, resulting in most patients being cured in 24 hours. Before it’s available in the U.S. the single-dose drug will need to pass FDA standard toxicity testing on animals, and undergo three phases of human trials to determine safety, effectiveness, dosage, and potential issues with other drugs.

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts